

## Disclosures

### Personal Commercial (11)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amarin	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Bayer Healthcare Pharmaceuticals	Data Safety Monitoring Board	Modest (< \$5,000)	Vascular Medicine
CiVi	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Esperion	Research/Research Grants	Modest (< \$5,000)	Acute Coronary Syndromes
Janssen Pharmaceuticals, Inc	Data Safety Monitoring Board	Modest (< \$5,000)	Vascular Medicine
Lexicon	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
NewAmsterdam	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Regeneron	Consultant Fees/Honoraria	Significant (>= \$5,000)	Acute Coronary Syndromes
Resverlogix	Consultant Fees/Honoraria	Modest (< \$5,000)	Acute Coronary Syndromes
Sanofi-Aventis	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
Silence	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2019	Patent infringement	Defendant † Sanofi-Aventis	Amgen sued Sanofi and Regeneron alleging patent infringement.	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 10/6/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/6/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 10/6/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 10/6/2023

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.